(All fields required)
Please enter a valid email.
Please enter your name.
What is : (So we know you are human.)
Please supply the correct answer.
Every year, researchers identify novel molecular aberrations associated with hematologic malignancies. Likewise, the advent of high-throughput sequencing projects will significantly expand the cadre of genes implicated in leukemogenesis. Understanding how these aberrant genes contribute to the development of various hematologic neoplasms is the major goal of the Hematologic Malignancies Program (HMP).
We are currently focusing on acute leukemia, myelodysplasia and myeloproliferative syndromes using a variety of approaches to model and dissect these diseases. One major approach is to use murine genetic models, including knockin, knockout and transgenic mice, to model the human diseases associated with loss or overexpression of individual genes. A complement to this approach is to use retroviral or lentiviral delivery to overexpress or knock down particular genes in primary human or murine blood stem and progenitor cells. In addition, our labs use patient samples as the ultimate validation of the findings obtained with these model systems.
HMP members have access to a world-class mouse core as part of the NIDDK-designated Center of Excellence in Hematology P30 core grant. This includes state-of-the-art xenograft models for expanding patient samples in vivo. Through these efforts, HMP members are testing new experimental therapies for hematologic malignancies.
The HMP facilitates interdisciplinary collaborations among researchers at Cincinnati Children’s and promotes a bench-to-bedside mentality that encourages clinicians and basic researchers to pool efforts and resources to achieve shared goals.
HMP members come from six divisions within Cincinnati Children’s and represent expertise in hematopoietic stem cell transplant, pathology, epigenetic modifications, human ES cell manipulation and the molecular biology and biochemistry of hematologic malignancy.
A major goal of the program is to study mechanisms regulating normal and malignant hematopoietic stem and progenitor cells and to develop therapies based on manipulating malignant stem cells using the knowledge gained through experimentation.
Lee Grimes, PhD program leaderMohammad Azam, PhDGang Huang, PhD
FacultyJames Mulloy, PhD co-program leaderLee Grimes, PhD co-program leaderMohammad Azam, PhDGang Huang, PhDAshish Kumar, MD, PhDBenjamin Mizukawa, MDDaniel T. Starcynowski, PhD
Adjunct FacultyDavid Plas, PhD - University of CincinnatiJim Driscoll, MD/PhD – University of Cincinnati Rhett Kovall, PhD - University of Cincinnati Eddie Merino, PhD - University of Cincinnati Vlad Litosh, PhD - University of Cincinnati
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026 | 1-513-636-4200 | 1-800-344-2462 | TTY: 1-513-636-4900
New to Cincinnati Children’s or live outside of the Tristate area? 1-877-881-8479
© 1999-2015 Cincinnati Children's Hospital Medical Center